HighPoint Advisor Group LLC Boosts Stock Position in Haleon plc (NYSE:HLN)

HighPoint Advisor Group LLC boosted its position in shares of Haleon plc (NYSE:HLN) by 6.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,768 shares of the company’s stock after acquiring an additional 2,213 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Haleon were worth $372,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of HLN. Wellington Management Group LLP lifted its holdings in Haleon by 67.5% during the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after buying an additional 6,175,835 shares in the last quarter. Douglas Lane & Associates LLC lifted its stake in Haleon by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after acquiring an additional 161,865 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Haleon by 18.3% in the fourth quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company’s stock worth $57,382,000 after acquiring an additional 930,701 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Haleon during the 4th quarter worth approximately $42,193,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Haleon in the 4th quarter valued at approximately $39,628,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Down 0.2 %

Haleon stock opened at $10.16 on Thursday. Haleon plc has a fifty-two week low of $7.99 and a fifty-two week high of $10.80. The firm has a market capitalization of $46.00 billion, a price-to-earnings ratio of 29.88, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The stock’s fifty day moving average is $10.00 and its two-hundred day moving average is $9.87. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Analysts predict that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently declared a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a $0.1166 dividend. This represents a yield of 1.6%. This is a positive change from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Analyst Upgrades and Downgrades

HLN has been the subject of a number of recent analyst reports. HSBC reaffirmed a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Finally, Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.